ClinicalTrials.gg
CompletedNCT02301975Updated Aug 6, 2018Results posted

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

A Phase 3 interventional study of Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler and Placebo inhalation powders via ELLIPTA inhaler in Asthma, sponsored by GlaxoSmithKline. Completed at 179 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-08-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,526
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
5th of 146
1,526 · median 100
Started
2015
with 6 others
Phase 3
35 of 147
none open now
Registered
110th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 5th largest by enrollment of the 146 interventional ones that give a count, is one of 7 that started in 2015, is one of 35 in phase 3, and was the 110th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, double-dummy, parallel group, multicenter, non-inferiority study. The study will enroll adult and adolescent asthmatic subjects who are currently receiving mid dose inhaled corticosteroids (ICS) plus long-acting beta2-agonist (LABA) (equivalent to fluticasone propionate [FP]/salmeterol 250/50 microgram [mcg]twice daily [BD]), either via a fixed dose combination product or through separate inhalers. The study consists of a LABA washout period of 5 days and a run-in period of 4 weeks, followed by a treatment period of 24 weeks, and a follow up contact period of one week. The total duration of the study is 30 weeks. Approximately 1461 subjects will be randomized to one of the following three treatments (487 per treatment): fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg once daily (OD) in the evening (PM) via ELLIPTA™ inhaler plus placebo BD via ACCUHALER™/DISKUS™; FP/salmeterol 250/50 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler; FP 250 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler. In addition, all subjects will be supplied with albuterol/salbutamol inhalation aerosol to use as needed to treat acute asthma symptoms. This study will determine if FF/VI 100/25 mcg OD via ELLIPTA inhaler is non-inferior to FP/salmeterol 250/50 mcg BD via ACCUHALER/DISKUS inhaler in adult and adolescent asthmatic subjects already adequately controlled on a twice-daily ICS/LABA.

SERETIDE, ELLIPTA, ACCUHALER, RELVAR, and DISKUS are trademarks of the GlaxoSmithKline Group of Companies.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Adult
  • asthma
  • Fluticasone Propionate
  • Adolescents
  • Salmeterol
  • Vilanterol
  • ELLIPTA
  • ACCUHALER/DISKUS
  • Non-inferior
  • Fluticasone Furoate
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Subjects must give their signed and dated written to participate prior to commencing any study related activities.
  • Subjects must be outpatients >=12 years of age at Visit 1 who have had a diagnosis of asthma, as defined by the National Institutes of Health, for at least 12 weeks prior to Visit 1 (Note: Countries with local restrictions prohibiting enrollment of adolescents will enroll subjects >=18 years of age only).
  • Subjects may be male or an eligible female. An eligible female is defined as having non- or having childbearing potential and a negative urine pregnancy test at Screening and agrees to use an acceptable method of consistently and correctly.
  • Subjects must have a of >=80% of the predicted normal value.
  • Subjects are eligible if they have received mid dose ICS plus LABA (equivalent to FP/salmeterol 250/50 twice daily or an equivalent combination via separate inhalers) for at least the 12 weeks immediately preceding Visit 1.
  • All subjects must be able to replace their current SABA treatment with albuterol/salbutamol aerosol inhaler at Visit 1 for use, as needed, for the duration of the study. Subjects must be able to withhold albuterol/salbutamol for at least 6 hours prior to study visits.
  • If in the opinion of the investigator the subject's asthma is well controlled. Exclusion Criteria
  • History of Life-Threatening Asthma, defined for this protocol as an asthma episode that required intubation and/or associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 5 years.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or in the opinion of the Investigator, expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Any asthma exacerbation requiring oral within 12 weeks of Visit 1 or resulting in an overnight hospitalization requiring additional treatment for asthma within 6 months prior to Visit 1.
  • A subject must not have current evidence of Atlectasis, Bronchopulmonary dysplasia, Chronic bronchitis, , Pneumonia, Pneumothorax, Interstitial lung disease, or any evidence of concurrent respiratory disease other than asthma
  • A subject must not have any , uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study.
  • A subject must not have used any drug within 30 days prior to Visit 1 or within five half-lives (t½) of the prior investigational study, whichever is longer of the two.
  • Any adverse reaction including immediate or delayed to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of RELVAR™ ELLIPTA inhaler, SERETIDE™ ACCUHALER/DISKUS inhaler or FP 250.
  • History of severe milk protein allergy.
  • Administration of prescription or non-prescription medication that would significantly affect the course of asthma, or interact with study drug.
  • A subject must not be using or require the use of medications during the study.
  • A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, disease, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol, including visit schedule and completion of the daily diaries.
  • Current tobacco smoker or has a smoking history of 10 pack-years (20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products or inhaled marijuana within the past 3 months (e.g., cigarettes, cigars, electronic cigarettes, or pipe tobacco).
  • A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,526 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/Vilanterol 100/25 mcg

    FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.

    Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler · Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler

  • Experimental
    Fluticasone Propionate/Salmeterol 250/50 mcg

    FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.

    Drug: Placebo inhalation powders via ELLIPTA inhaler · Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler

  • Experimental
    Fluticasone Propionate 250 mcg

    FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.

    Drug: Placebo inhalation powders via ELLIPTA inhaler · Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler

Interventions

  • DrugFluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler

    FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.

  • DrugPlacebo inhalation powders via ELLIPTA inhaler

    Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.

  • DrugFluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler

    FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.

  • DrugPlacebo inhalation powder via ACCUHALER/DISKUS inhaler

    Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.

  • DrugFluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler

    Drug page: Fluticasone

    FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population

    FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the mixed model repeated measures (MMRM) model and least square mean and standard error were calculated. The analysis was performed on ITT Population which comprised of all participants randomized to treatment and who received at least one dose of study medication.

    Time frame: Baseline and Week 24

  2. Change From Baseline in PM FEV1 Using Per Protocol (PP) Population

    FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the MMRM models and least square mean and standard error were calculated. The analysis was performed on PP Population which comprised of all participants in the ITT Population who did not had any full protocol deviations.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in the Percentage of Rescue-free 24-hour Periods

    The number of inhalations of rescue medication used during the day and night were recorded by participants using an electronic diary (e-diary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.

    Time frame: Baseline and Weeks 1-24

  2. Change From Baseline in the Percentage of Symptom-free 24-hour Periods

    Change from Baseline in the percentage of symptom-free 24 hour period was evaluated. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value.Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.

    Time frame: Baseline and Weeks 1-24

  3. Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF)

    PEF was measured using an electric flow meter each morning. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.

    Time frame: Baseline and Weeks 1-24

  4. Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20

    The ACT was a five-item questionnaire developed as a measure of participant's asthma control. The percentage of participants controlled, defined as having ACT score greater than or equal to 20 at the end of Week 24 were analyzed using logistic regression model with covariates of Baseline ACT score, region, sex, age and treatment group.

    Time frame: Week 24

  5. Change From Baseline in PM PEF

    PEF was measured using an electric flow meter each evening. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.

    Time frame: Baseline and Weeks 1-24

07

Results

Posted Jun 12, 2017

Participant flow

Eligible participants at screening and run-in visits entered a 24 Week treatment period and were randomized to receive either Fluticasone furoate/Vilanterol (FF/VI) 100/25 micrograms (mcg) or Fluticasone propionate/salmeterol (FP/S) 250/50mcg or only FP 250mcg followed by a follow-up phase. The total duration for study participation was 30 weeks.

Participant flow — Overall Study
MilestoneFF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Started504501499
Completed473476477
Not completed312522
Withdrew: Adverse event832
Withdrew: Lack of efficacy111
Withdrew: Protocol violation353
Withdrew: Lost to follow-up022
Withdrew: Physician decision423
Withdrew: Withdrawal by subject151211

Outcome measures

PrimaryChange From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population

FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the mixed model repeated measures (MMRM) model and least square mean and standard error were calculated. The analysis was performed on ITT Population which comprised of all participants randomized to treatment and who received at least one dose of study medication.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Liter (L)
Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population
Liter (L)FF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population0.019 ± 0.01070.000 ± 0.0108-0.104 ± 0.0109
Statistical analysis
  • FF/VI 100/25 mcg Once Daily vs FP/S 250/50 mcg Twice Daily · Least square mean change difference: 0.019 · 95% CI -0.011 to 0.049
  • FF/VI 100/25 mcg Once Daily vs FP 250 mcg Twice Daily · Mixed Models Analysis · p = <0.001 · Least square mean change difference: 0.123 · 95% CI 0.093 to 0.153
  • FP/S 250/50 mcg Twice Daily vs FP 250 mcg Twice Daily · Mixed Models Analysis · p = <0.001 · Least square mean change difference: 0.104 · 95% CI 0.074 to 0.134
PrimaryChange From Baseline in PM FEV1 Using Per Protocol (PP) Population

FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the MMRM models and least square mean and standard error were calculated. The analysis was performed on PP Population which comprised of all participants in the ITT Population who did not had any full protocol deviations.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · L
Change From Baseline in PM FEV1 Using Per Protocol (PP) Population
LFF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Change From Baseline in PM FEV1 Using Per Protocol (PP) Population0.020 ± 0.01200.014 ± 0.0120-0.099 ± 0.0121
Statistical analysis
  • FF/VI 100/25 mcg Once Daily vs FP/S 250/50 mcg Twice Daily · Least square mean change difference: 0.006 · 95% CI -0.027 to 0.040
  • FF/VI 100/25 mcg Once Daily vs FP 250 mcg Twice Daily · Mixed Models Analysis · p = <0.001 · Least square mean change difference: 0.120 · 95% CI 0.086 to 0.153
  • FP/S 250/50 mcg Twice Daily vs FP 250 mcg Twice Daily · Mixed Models Analysis · p = <0.001 · Least square mean change difference: 0.113 · 95% CI 0.080 to 0.147
SecondaryChange From Baseline in the Percentage of Rescue-free 24-hour Periods

The number of inhalations of rescue medication used during the day and night were recorded by participants using an electronic diary (e-diary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.

Time frame:
Baseline and Weeks 1-24
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Change From Baseline in the Percentage of Rescue-free 24-hour Periods
Percentage of rescue-free 24-hr periodsFF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Change From Baseline in the Percentage of Rescue-free 24-hour Periods-3.0 ± 0.62-4.2 ± 0.62-5.7 ± 0.62
Statistical analysis
  • FF/VI 100/25 mcg Once Daily vs FP/S 250/50 mcg Twice Daily · Least square mean change difference: 1.2 · 95% CI -0.5 to 3.0
  • FF/VI 100/25 mcg Once Daily vs FP 250 mcg Twice Daily · ANCOVA · p = 0.002 · Least square mean change difference: 2.7 · 95% CI 0.9 to 4.4
  • FP/S 250/50 mcg Twice Daily vs FP 250 mcg Twice Daily · ANCOVA · p = 0.106 · Least square mean change difference: 1.4 · 95% CI -0.3 to 3.2
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour Periods

Change from Baseline in the percentage of symptom-free 24 hour period was evaluated. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value.Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.

Time frame:
Baseline and Weeks 1-24
Reported as:
Least squares mean · Percentage of symptom-free 24 hour perio
Change From Baseline in the Percentage of Symptom-free 24-hour Periods
Percentage of symptom-free 24 hour perioFF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Change From Baseline in the Percentage of Symptom-free 24-hour Periods-3.5 ± 0.67-4.7 ± 0.67-6.2 ± 0.67
Statistical analysis
  • FF/VI 100/25 mcg Once Daily vs FP/S 250/50 mcg Twice Daily · Least square mean change difference: 1.2 · 95% CI -0.7 to 3.1
  • FF/VI 100/25 mcg Once Daily vs FP 250 mcg Twice Daily · ANCOVA · p = 0.004 · Least square mean change difference: 2.7 · 95% CI 0.8 to 4.5
  • FP/S 250/50 mcg Twice Daily vs FP 250 mcg Twice Daily · ANCOVA · p = 0.115 · Least square mean change difference: 1.5 · 95% CI -0.4 to 3.3
SecondaryChange From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF)

PEF was measured using an electric flow meter each morning. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.

Time frame:
Baseline and Weeks 1-24
Reported as:
Least squares mean · Liter per minute (L/min)
Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF)
Liter per minute (L/min)FF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF)8.9 ± 1.483.7 ± 1.49-12.6 ± 1.49
Statistical analysis
  • FF/VI 100/25 mcg Once Daily vs FP/S 250/50 mcg Twice Daily · Least square mean change difference: 5.2 · 95% CI 1.1 to 9.4
  • FF/VI 100/25 mcg Once Daily vs FP 250 mcg Twice Daily · ANCOVA · p = <0.001 · Least square mean change difference: 21.5 · 95% CI 17.4 to 25.6
  • FP/S 250/50 mcg Twice Daily vs FP 250 mcg Twice Daily · ANCOVA · p = <0.001 · Least square mean change difference: 16.3 · 95% CI 12.2 to 20.4
SecondaryPercentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20

The ACT was a five-item questionnaire developed as a measure of participant's asthma control. The percentage of participants controlled, defined as having ACT score greater than or equal to 20 at the end of Week 24 were analyzed using logistic regression model with covariates of Baseline ACT score, region, sex, age and treatment group.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20
Percentage of participantsFF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20929391
Statistical analysis
  • FF/VI 100/25 mcg Once Daily vs FP/S 250/50 mcg Twice Daily · Odds ratio (or): 0.91 · 95% CI 0.53 to 1.54
  • FF/VI 100/25 mcg Once Daily vs FP 250 mcg Twice Daily · Regression, Logistic · p = 0.595 · Odds ratio (or): 1.15 · 95% CI 0.69 to 1.90
  • FP/S 250/50 mcg Twice Daily vs FP 250 mcg Twice Daily · Regression, Logistic · p = 0.372 · Odds ratio (or): 1.27 · 95% CI 0.75 to 2.12
SecondaryChange From Baseline in PM PEF

PEF was measured using an electric flow meter each evening. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.

Time frame:
Baseline and Weeks 1-24
Reported as:
Least squares mean · L/min
Change From Baseline in PM PEF
L/minFF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Change From Baseline in PM PEF5.5 ± 1.550.5 ± 1.55-13.7 ± 1.55
Statistical analysis
  • FF/VI 100/25 mcg Once Daily vs FP/S 250/50 mcg Twice Daily · Least square mean change difference: 5.0 · 95% CI 0.7 to 9.3
  • FF/VI 100/25 mcg Once Daily vs FP 250 mcg Twice Daily · ANCOVA · p = <0.001 · Least square mean change difference: 19.2 · 95% CI 14.9 to 23.5
  • FP/S 250/50 mcg Twice Daily vs FP 250 mcg Twice Daily · ANCOVA · p = <0.001 · Least square mean change difference: 14.2 · 95% CI 9.9 to 18.5

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment until the follow up contact one week after completion of study medication (Up to Week 25).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF/VI 100/25 mcg Once Daily0/504 (0%)6/504 (1.2%)126/504 (25%)
FP/S 250/50 mcg Twice Daily0/501 (0%)4/501 (0.8%)123/501 (24.6%)
FP 250 mcg Twice Daily0/499 (0%)5/499 (1%)124/499 (24.8%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventFF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
Cholecystitis acuteHepatobiliary disorders0/5040/5011/499
Abdominal abscessInfections and infestations0/5040/5011/499
Foot fractureInjury, poisoning and procedural complications0/5040/5011/499
Joint instabilityMusculoskeletal and connective tissue disorders0/5040/5011/499
OsteoarthritisMusculoskeletal and connective tissue disorders0/5040/5011/499
HypertensionVascular disorders0/5040/5011/499
Large intestine perforationGastrointestinal disorders0/5041/5010/499
EpilepsyNervous system disorders0/5041/5010/499
Psychotic disorderPsychiatric disorders0/5041/5010/499
Vocal cord leukoplakiaRespiratory, thoracic and mediastinal disorders0/5041/5010/499
Most frequent other events
Most frequent other events
EventFF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice Daily
NasopharyngitisInfections and infestations61/50467/50157/499
HeadacheNervous system disorders41/50437/50140/499
BronchitisInfections and infestations20/50410/50113/499
InfluenzaInfections and infestations9/50412/50119/499
PharyngitisInfections and infestations15/50413/50118/499

Baseline characteristics

Age, Continuous
Age, Continuous(Participants)FF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice DailyTotal
Mean44.4 ± 16.3043.0 ± 15.2043.0 ± 16.5843.5 ± 16.04
Sex: Female, Male
Sex: Female, Male(Participants)FF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice DailyTotal
Female314336314964
Male190165185540
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FF/VI 100/25 mcg Once DailyFP/S 250/50 mcg Twice DailyFP 250 mcg Twice DailyTotal
American Indian or Alaska native0011
Asian - East Asian Heritage811423
Asian- Japanese Heritage1001
Asian- South East Asian Heritage1012
Black/African American Heritage12141743
White- Arabic/ North African Heritage0123
White- White/Caucasian/European Heritage4154074101232
White- Mixed White Race1001
African American/ African and White Heritage0505
American Indian/Alaskan Native and White Heritage666264192
Asian - East Asian and White Heritage0101
08

Study locations

179 sites
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    Upland, California 91786, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Miami, Florida 33165, United States
  • GSK Investigational Site
    Miami, Florida 33174, United States
  • GSK Investigational Site
    Albany, Georgia 31707, United States
  • GSK Investigational Site
    Baltimore, Maryland 21236, United States
  • GSK Investigational Site
    Columbia, Maryland 21044, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Plymouth, Minnesota 55441, United States
  • GSK Investigational Site
    Columbia, Missouri 65203, United States
  • GSK Investigational Site
    Rolla, Missouri 65401, United States
  • GSK Investigational Site
    Bellevue, Nebraska 68123-4303, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28277, United States
  • GSK Investigational Site
    Gastonia, North Carolina 28054, United States
  • GSK Investigational Site
    Hendersonville, North Carolina 28739, United States
  • GSK Investigational Site
    Huntersville, North Carolina 28078, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Middleburg Heights, Ohio 44130, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18020, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    Lewisville, Texas 75067, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Richmond, Virginia 23225, United States
  • GSK Investigational Site
    Greenfield, Wisconsin 53228, United States
  • GSK Investigational Site
    Florida, Buenos Aires 1602, Argentina
  • GSK Investigational Site
    La Plata, Buenos Aires 1900, Argentina
  • GSK Investigational Site
    Mar del Plata, Buenos Aires 7600, Argentina
  • GSK Investigational Site
    Quilmes, Buenos Aires B1878FNR, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000DBS, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000JKR, Argentina
  • GSK Investigational Site
    Buenos Aires, C1424BSF, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1121ABE, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mar del Plata, B7600FYK, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, 4000, Argentina
  • GSK Investigational Site
    Salvador, Bahía 41940455, Brazil
  • GSK Investigational Site
    Goiânia, Goiás 74110 030, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • GSK Investigational Site
    São Paulo, 01323903, Brazil
  • GSK Investigational Site
    São Paulo, 04266-010, Brazil
  • GSK Investigational Site
    Concepción, Región Del Biobio 4070038, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500692, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500710, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7510186, Chile
  • GSK Investigational Site
    Valparaiso, Valparaíso 2341131, Chile
  • GSK Investigational Site
    Santiago, 7500698, Chile
  • GSK Investigational Site
    Viña del Mar, 2520594, Chile
  • GSK Investigational Site
    Ceska Lipa, 470 01, Czechia
  • GSK Investigational Site
    Hlucin, 748 01, Czechia
  • GSK Investigational Site
    Hradec Kralove, 500 02, Czechia
  • GSK Investigational Site
    Kutna Hora, 284 01, Czechia
  • GSK Investigational Site
    Lovosice, 410 02, Czechia
  • GSK Investigational Site
    Olomouc, 772 00, Czechia
  • GSK Investigational Site
    Ostrava - Poruba, 70868, Czechia
  • GSK Investigational Site
    Rokycany, 337 01, Czechia
  • GSK Investigational Site
    Tabor, 390 01, Czechia
  • GSK Investigational Site
    Teplice, 415 10, Czechia
  • GSK Investigational Site
    Varnsdorf, 407 47, Czechia
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70378, Germany
  • GSK Investigational Site
    Bamberg, Bayern 96049, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80339, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80539, Germany
  • GSK Investigational Site
    Potsdam, Brandenburg 14469, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Marburg, Hessen 35037, Germany
  • GSK Investigational Site
    Neu isenburg, Hessen 63263, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30173, Germany
  • GSK Investigational Site
    Peine, Niedersachsen 31224, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45355, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Warendorf, Nordrhein-Westfalen 48231, Germany
  • GSK Investigational Site
    Witten, Nordrhein-Westfalen 58452, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • GSK Investigational Site
    Teuchern, Sachsen-Anhalt 6682, Germany
  • GSK Investigational Site
    Delitzsch, Sachsen 04509, Germany
  • GSK Investigational Site
    Leipzg, Sachsen 04109, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04207, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04275, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04357, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23552, Germany
  • GSK Investigational Site
    Schleswig, Schleswig-Holstein 24837, Germany
  • GSK Investigational Site
    Schmoelln, Thueringen 04626, Germany
  • GSK Investigational Site
    Berlin, 10119, Germany
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany

Showing the first 100 of 179 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bernstein D, Andersen L, Forth R, Jacques L, Yates L. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA. J Asthma. 2018 Sep;55(9):984-993. doi: 10.1080/02770903.2017.1386214. Epub 2018 Apr 13. PubMed 28961020 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2014
First posted
Nov 26, 2014
Start
Mar 1, 2015
Primary completionActual
Nov 1, 2016
CompletionActual
Nov 25, 2016
Results first posted
Jun 12, 2017
Last update
Aug 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02301975
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 26, 2014
Start date
Mar 1, 2015
Primary completion
Nov 1, 2016
Completion
Nov 25, 2016
Results posted
Jun 12, 2017
Last update
Aug 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion